Skip to main content
Erschienen in: International Urogynecology Journal 11/2014

01.11.2014 | Original Article

The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment

verfasst von: Mehmet Ali Sekeroglu, Emre Hekimoglu, İkbal Seza Petricli, Yasemin Tasci, Ismail Dolen, Umut Arslan

Erschienen in: International Urogynecology Journal | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Anticholinergic medication is the mainstay of pharmacotherapy for overactive bladder (OAB). The aim of the study is to investigate the effect of oral solifenacin succinate on intraocular pressure (IOP) in female OAB patients and to discuss the ocular drawbacks during treatment.

Methods

The female patients with a clinical diagnosis of OAB in whom use of oral solifenacin succinate 5 mg/day (group I) and age-matched healthy female subjects (group II) underwent complete ophthalmological examination, including IOP measurement at the beginning of the oral treatment and after 4 weeks. The patients with a history of previous ocular surgery and those with ocular diseases besides refraction disorders and presbyopia were excluded.

Results

The data from the right eyes of 60 consecutive patients in group I and 30 consecutive patients in group II were used for analysis. No statistically significant change was detected in the IOP (from 16.05 ± 2.30 mmHg to 16.30 ± 2.25 mmHg at the 4th week in group I, p = 0.160; from 15.60 ± 2.14 mmHg to 15.60 ± 2.09 mmHg at the 4th week in group II, p = 0.864) of the eyes in both groups.

Conclusions

Since the power of the study is not enough to draw a clear conclusion, a 4-week course of solifenacin succinate treatment in women with OAB seemed to have no clinically significant effect on IOP values. Further larger studies are needed to determine the effect of anticholinergics on anterior chamber parameters and to evaluate their safety in glaucoma patients.
Literatur
1.
Zurück zum Zitat Abrams P, Cardozo L, Fall M (2003) Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49PubMedCrossRef Abrams P, Cardozo L, Fall M (2003) Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49PubMedCrossRef
2.
Zurück zum Zitat Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26. doi:10.1007/s00192-009-0976-9 PubMedCrossRef Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26. doi:10.​1007/​s00192-009-0976-9 PubMedCrossRef
3.
Zurück zum Zitat Gormley EA, Lightner DJ, Burgio KL (2012) American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 188(6 Suppl):2455–2463PubMedCrossRef Gormley EA, Lightner DJ, Burgio KL (2012) American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 188(6 Suppl):2455–2463PubMedCrossRef
4.
Zurück zum Zitat Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3(1):46–53PubMedCrossRef Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3(1):46–53PubMedCrossRef
5.
Zurück zum Zitat Tripathi RC, Tripathi BJ, Haggerty C (2003) Drug-induced glaucomas: mechanism and management. Drug Saf 26(11):749–767PubMedCrossRef Tripathi RC, Tripathi BJ, Haggerty C (2003) Drug-induced glaucomas: mechanism and management. Drug Saf 26(11):749–767PubMedCrossRef
6.
Zurück zum Zitat Garely AD, Kaufman JM, Sand PK et al (2006) Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 28(11):1935–1946PubMedCrossRef Garely AD, Kaufman JM, Sand PK et al (2006) Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 28(11):1935–1946PubMedCrossRef
7.
Zurück zum Zitat Sung VC, Corridan PG (1998) Acute-angle closure glaucoma as a side-effect of oxybutynin. Br J Urol 81(4):634–635PubMedCrossRef Sung VC, Corridan PG (1998) Acute-angle closure glaucoma as a side-effect of oxybutynin. Br J Urol 81(4):634–635PubMedCrossRef
8.
Zurück zum Zitat Ouslander JG, Blaustein J, Connor A et al (1988) Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 140(1):47–50PubMed Ouslander JG, Blaustein J, Connor A et al (1988) Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 140(1):47–50PubMed
9.
Zurück zum Zitat Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y et al (2005) Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 59(5):588–592PubMedCrossRefPubMedCentral Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y et al (2005) Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 59(5):588–592PubMedCrossRefPubMedCentral
10.
Zurück zum Zitat Frischmeyer KJ, Miller PE, Bellay Y et al (1993) Parenteral anticholinergics in dogs with normal and elevated intraocular pressure. Vet Surg 22(3):230–234PubMedCrossRef Frischmeyer KJ, Miller PE, Bellay Y et al (1993) Parenteral anticholinergics in dogs with normal and elevated intraocular pressure. Vet Surg 22(3):230–234PubMedCrossRef
11.
Zurück zum Zitat Homma Y, Kakizaki H, Gotoh M et al (2003) Epidemiologic survey on urination. J Jpn Neurogenic Bladder Soc 14:266–277 Homma Y, Kakizaki H, Gotoh M et al (2003) Epidemiologic survey on urination. J Jpn Neurogenic Bladder Soc 14:266–277
12.
Zurück zum Zitat Iwase A (2003) The prevalence of glaucoma in Japan. Ganka 45:733–739 Iwase A (2003) The prevalence of glaucoma in Japan. Ganka 45:733–739
13.
Zurück zum Zitat Kato K, Furuhashi K, Suzuki K et al (2007) Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol 14(7):595–597PubMedCrossRef Kato K, Furuhashi K, Suzuki K et al (2007) Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol 14(7):595–597PubMedCrossRef
14.
Zurück zum Zitat Kato K, Yoshida K, Suzuki K et al (2005) Managing patients with an overactive bladder and glaucoma: a questionnaire survey of Japanese urologists on the use of anticholinergics. BJU Int 95(1):98–101PubMedCrossRef Kato K, Yoshida K, Suzuki K et al (2005) Managing patients with an overactive bladder and glaucoma: a questionnaire survey of Japanese urologists on the use of anticholinergics. BJU Int 95(1):98–101PubMedCrossRef
15.
Zurück zum Zitat Fink AM, Aylward GW (1995) Buscopan and glaucoma: a survey of current practice. Clin Radiol 50(3):160–164PubMedCrossRef Fink AM, Aylward GW (1995) Buscopan and glaucoma: a survey of current practice. Clin Radiol 50(3):160–164PubMedCrossRef
Metadaten
Titel
The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment
verfasst von
Mehmet Ali Sekeroglu
Emre Hekimoglu
İkbal Seza Petricli
Yasemin Tasci
Ismail Dolen
Umut Arslan
Publikationsdatum
01.11.2014
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 11/2014
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-014-2396-8

Weitere Artikel der Ausgabe 11/2014

International Urogynecology Journal 11/2014 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.